Okyo Pharma price target raised to $5 from $4 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on Okyo Pharma to $5 from $4 and keeps a Buy rating on the shares. The fact that statistically significant data showed up as early as 15 days after drug dosing demonstrates OK-101’s fast onset of action, the analyst tells investors in a research note.